Drugs / BCG intravesical live (TICE Bacillus Calmette-Guerin (BCG))
BCG intravesical live (TICE Bacillus Calmette-Guerin (BCG))
also known as
TICE Bacillus Calmette-Guerin (BCG)
Trials 0
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Comparator or background therapy1 trial | ||||||
| Phase 2 | NCT02015104 Background | Dec 2013 → Sep 2018 | urinary bladder cancer | National Cancer Institute (NCI) | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | BCG intravesical live (TICE Bacillus Calmette-Guerin (BCG)) | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02015104 ↗ |
| Known as | TICE Bacillus Calmette-Guerin (BCG) | “BCG intravesical live (TICE Bacillus Calmette-Guerin (BCG))” NCT02015104 ↗ |
| Modality | Other / unclassified | “TICE BCG for intravesical use, is an attenuated, live culture preparation” NCT02015104 ↗ |